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clinically due to the number of variables 
that need to be investigated to control and 
optimize the effect. Various groups have 
investigated different aspects, such as 
varying NP size or radiation beam energy. 
Even with knowledge from these studies, 
there is still a considerable amount of 
variability in reported findings. Differ-
ences are caused by the diversity in cell 
lines, NPs with their respective coatings, 
incubated NP concentrations, incubation 
times, irradiation parameters, as well as 
the assays used to demonstrate the effects. 
This has led to variations in the results, 
where significant enhancements of a 
factor of 25 were shown by Rahman et al., 
with Aurovist 1.9 nm gold nanoparticles 
(AuNPs) at a concentration of 1 mm with 
bovine aortic endothelial cells (BAEC) 
and 80 kV X-rays,[3] compared to smaller 
enhancements shown by Chithrani et al., 
where they synthesized 50 nm AuNPs at a 
concentration of approximately 1 nm in HeLa cells and found an 
enhancement factor of 1.17 with 6 MV X-rays.[4] As well as this, 
there are also differences in protocols between research groups, 
in both maintenance of cells and assays reported.
A review by Her et al. reported on the different mechanisms 
associated with NP-enhanced radiotherapy, where the overall 
effect is a combination of physical, chemical, and biological 
Materials with a high atomic number (Z) are shown to cause an increase 
in the level of cell kill by ionizing radiation when introduced into tumor 
cells. This study uses in vitro experiments to investigate the differences 
in radiosensitization between two cell lines (MCF-7 and U87) and three 
commercially available nanoparticles (gold, gadolinium, and iron oxide) 
irradiated by 6 MV X-rays. To assess cell survival, clonogenic assays are 
carried out for all variables considered, with a concentration of 0.5 mg mL-1 
for each nanoparticle material used. This study demonstrates differ-
ences in cell survival between nanoparticles and cell line. U87 shows the 
greatest enhancement with gadolinium nanoparticles (2.02 ± 0.36), whereas 
MCF-7 cells have higher enhancement with gold nanoparticles (1.74 ± 0.08). 
Mass spectrometry, however, shows highest elemental uptake with iron oxide 
and U87 cells with 4.95 ± 0.82 pg of iron oxide per cell. A complex relation-
ship between cellular elemental uptake is demonstrated, highlighting an 
inverse correlation with the enhancement, but a positive relation with DNA 
damage when comparing the same nanoparticle between the two cell lines.
1. Introduction
It has been shown over the years that nanoparticles (NPs) can 
be used to locally enhance the level of dose deposition,[1] and 
even in some instances cause tumors to be more sensitive to 
the damaging effects of ionizing radiation.[2] Although this form 
of treatment has shown much promise, it is not currently used 
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mechanisms.[5] In terms of the physical mechanisms, this was 
attributed to an increase in secondary electrons, where differ-
ences in NP size and composition can first lead to differences in 
interactions with the NPs, but also the number of electrons pro-
duced with sufficient energy to carry out further ionizations.[6] 
Due to these physical mechanisms, it was initially predicted 
that NP-enhanced radiotherapy would only be effective with low 
energy X-rays due to difference in mass energy absorption coeffi-
cients between soft tissue and high-Z materials, which decreased 
with increasing incident X-ray energy. However, following both 
in vivo and in vitro experiments, significant enhancements were 
shown with higher energies, demonstrating that other mecha-
nisms were involved in NP-enhanced radiotherapy. Therefore, 
other mechanisms were investigated, such as chemical mecha-
nisms. It has been suggested that this involves NPs chemically 
sensitizing DNA to the damaging effects of radiation, but also 
increasing radical formations due to the incident radiation acti-
vating the surface atoms of NPs.[7] Finally, biological mecha-
nisms were studied, reported as an increase in reactive oxygen 
species (ROS) formation,[8] oxidative stress,[9] inhibition of DNA 
repair,[10] and changes to the cell cycle.[11]
To further understand the impact of introducing NPs into a cell, 
two different variables were considered, i) NP material and ii) cell 
type, all irradiated with 6 MV X-rays. Focus was directed on these 
variables, as the relationship between NP material and cell type 
has not been characterized in terms of enhancement effect related 
to cellular uptake, where it has been theorized that an increase in 
cellular uptake would correlate with a higher enhancement effect. 
Findings from this work were related to the possible mechanisms 
that may have regulated any observed enhancement.
As the NP material can affect the radiosensitization effect, 
three commercially available NP types were investigated. The 
first were spherical AuNPs (Aurovist, Nanoprobes Inc, NY, 
USA; mean diameter 1.9 ± 0.6 nm, lot number 33C867), with 
a thiol coating.[12] These NPs were used by Hainfeld et al. in 
the first study demonstrating in vivo NP-enhanced radiation 
therapy. Second were spherical gadolinium-based NPs (GdNPs) 
(AGuIX, NH TherAguix, France; mean diameter 3.0 ± 1.5 nm, 
batch number 2019-01a), comprising a polysiloxane matrix with 
cyclic chelates of gadolinium.[13–15] These NPs have recently 
completed a phase I clinical trial and are currently in a phase 
II trial (NANORAD2).[16] Finally, spherical iron oxide NPs 
(IONPs) (RCL-01, Resonant Circuits Limited, UK; mean diam-
eter 140 ± 4 nm, polydispersity index 0.25 ± 0.02, batch number 
2018–151) were considered.[17] IONPs have been used in cancer 
therapy through magnetic hyperthermia, where the NPs produce 
heat when exposed to a high-frequency alternating magnetic 
field.[18] Although IONPs have not been explicitly investigated in 
NP-enhanced radiotherapy, they have undergone several in vitro 
studies for hyperthermia applications, where they have demon-
strated cellular uptake.[19] It was therefore of interest to determine 
if these larger-sized NPs would demonstrate similar enhance-
ments to the other NPs considered, when combined with radio-
therapy. All NP materials have a sufficiently high atomic number 
to observe the predicted radiosensitization effect.[20,21] For all NP 
materials, the same incubation time (24 h) and concentration of 
0.5 mg mL−1 was used, such that comparisons could be made. 
This concentration was shown by Jain et al. to be effective for 
radiosensitization,[22] when using Aurovist 1.9 nm AuNPs.
The other variable considered was the cell type, which could 
demonstrate in which cases NPs may be most beneficial. Two 
cell types were investigated, MCF-7, a human breast adeno-
carcinoma cell line, and U87, a human glioblastoma cell line. 
Both of these cell lines are well characterized and extensively 
studied within the literature. They demonstrate two different 
cancer types, where differences in cellular uptake and radia-
tion response were expected; therefore, it allows for trends to 
be identified across the two cell lines and the different NPs con-
sidered. It has been shown in the literature that depending on 
the cell type, differences in NP uptake can occur due to char-
acteristics of the microenvironment, affecting NPs internalized 
within the cell.[23] Other factors such as the surface-to-volume 
ratio can affect uptake, as a larger ratio increases the probability 
of interacting with cellular receptors for uptake.[24] Differences 
in uptake across NPs and cell lines were demonstrated by Dos 
Santos et al., where they investigated the level of uptake in five 
different cell lines, with negatively charged carboxylated poly-
styrene (PS–COOH) NPs ranging from 40–500 nm to micrometer-
sized objects (1 and 2 µm).[25] At a concentration of 20 µg mL−1  
(24 h incubation), they demonstrated a decrease in cellular 
uptake with increasing NP size across all cell lines tested. 
Another aspect is that different cells will respond to radiation 
differently, where some are more radioresistant, in which case 
the use of NPs is of particular interest, as it may radiosensitize 
the cells. The reason for differences in radiosensitivity between 
cells is not fully understood but thought to be due to factors 
such as differences in ability to repair damage.[26]
These studies have demonstrated the difficulties in assessing 
the most optimum setup for NP-enhanced radiotherapy, due to 
the variability in cell type, NP, and beam characteristics consid-
ered. A cooperative of stakeholders reported recommendations 
to standardize reporting on the efficacy of NP-enhanced radio-
therapy, highlighting metrics such as NP cellular uptake and 
cell survival (using fitting parameters α and β obtained from 
the linear-quadratic (LQ) model), as well as quoting an enhance-
ment ratio at a dose level of 2 Gy.[27,28] These reports also high-
lighted that although the α/β ratio would indicate changes in 
radiosensitivity due to the addition of NPs, no study has cur-
rently incorporated this metric within their analysis of the 
enhancement effect. An interesting aspect of this is to compare 
findings with the literature on samples irradiated with higher 
linear energy transfer (LET) radiation, such as protons, which 
show an increased relative biological effectiveness (RBE) due to 
more densely ionizing incident radiation.[29] By comparing with 
in vitro studies that irradiate samples with protons, it is possible 
to determine if the addition of NPs can alter the α/β ratio of 
X-ray irradiations to be comparable to radiation with a higher 
LET (protons). Finally, the quantification of DNA damage in the 
form of immunofluorescence staining has been identified as 
a key factor regulating radiation response, which needs to be 
quantified in terms of NP-enhanced radiotherapy. Therefore, 
this study aims to unify these key metrics in a parameterized 
study, considering the effect of NP type on cell line, relating cell 
survival and DNA damage to cellular uptake. This was demon-
strated through both clonogenic assays, quantifying cell survival 
post-irradiation, and the 53BP1 foci formation assay, which 
quantifies DNA double-strand break (DSB) repair through 
the marker 53BP1.[30,31] Both results were compared to uptake 
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measurements using inductively coupled plasma mass spec-
trometry (ICP-MS). The results from this study offer an under-
standing of the biological impact of using NPs though an in 
vitro study, comparing variability in biological effect across both 
cell line and NP types and relating findings with cellular uptake.
2. Results
2.1. Nanoparticle Cytotoxicity
The effect of a 24 h exposure to NPs was assessed through the 
clonogenic assay as shown in Figure 1. It can be seen that for 
both concentrations considered, all three NPs has no impact 
on the cells ability to produce colonies for either cell line 
considered.
2.2. Nanoparticle Uptake
Using ICP-MS, differences in cellular uptake were reported 
between cell lines and nanoparticle types following a 24 h incu-
bation period. Figure 2 shows that the highest uptake was with 
U87 cells and IONPs. Significance was demonstrated between 
all NPs for U87 cells, whereas with MCF-7 cells, no significant 
difference in cellular uptake was shown between the NPs con-
sidered. When comparing the uptake for the same NP, the only 
significance demonstrated was with IONPs, whereas no signifi-
cant differences were shown with the other NPs between the 
two cell lines.
2.3. Clonogenic Variations Due to the Addition of NPs
Figure 3 demonstrates the cell survival with and without NPs 
for both cell lines, where the α/β ratios were determined for all 
curves and significant changes were shown due to the addition 
of NPs, for all types considered, with both cell lines (Table 1). 
For U87 cells, the α/β ratios were 86.1 ± 41.5 Gy (p = 0.029), 
20.5 ± 8.73 Gy (p = 0.047), and 20.5 ± 8.90 Gy (p = 0.049) for 
GdNPs, AuNPs, and IONPs, respectively, compared to a ratio 
of 6.02 ± 1.19 Gy for cells alone. For MCF-7 cells, ratios were 
39.6 ± 15.6 Gy (p = 0.021), 39.3 ± 17.4 Gy (p = 0.030), and 
22.9 ± 9.91 Gy (p = 0.044) for GdNPs, AuNPs, and IONPs, 
respectively, compared to a ratio of 6.15 ± 1.32 Gy for cells 
alone, where p-values quoted compare samples with NPs to the 
control without NPs. An increase in the α/β ratio signifies that 
tumor response is less dependent on the dose per fraction, 
therefore a lower dose can be used.[32] An interesting point 
was the significant decrease in β for U87 cells with GdNPs, 
where a decrease in β indicates a smaller proportion of repair-
able cell damage. Having shown a significance between NPs 
and the control (Table 1, p-value1), comparisons were made 
for the same NP between the two cell lines (Table 1, p-value5), 
where no significance was shown for all NPs considered, dem-
onstrating that the NPs had a biological effect independent of 
the cell line considered.
2.4. Enhancement Factors
For U87 cells, all NPs considered caused an increase in the level 
of cell kill, where the highest was with GdNPs showing an EF 
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Figure 1. Cytotoxic effect of nanoparticles on clonogenic survival, carried out in triplicate, following 24-h exposure to a concentration of A) 0.2 mg mL−1 
and B) 0.5 mg mL−1 of each respective nanoparticle material. Surviving fractions were normalized to untreated control cells in each experiment.
Figure 2. Uptake measurements, carried out in triplicate, determined 
using mass-spectrometry where results were quoted as pg of gold, gado-
linium, and iron oxide per cell. p-Values represent comparisons between 
the three NP types for each cell line, whereas p* values represent com-
parisons of the same NP across both cell lines.
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of 2.02 ± 0.36 (p = 0.008), as shown in Figure 4, where it was 
1.27 ± 0.12 (p = 0.020) and 1.26 ± 0.07 (p = 0.004) for AuNPs 
and IONPs, respectively. With MCF-7 cells, the highest EF was 
1.74 ± 0.08 (p < 0.001) with AuNPs, compared to 1.58 ± 0.10 
(p = 0.001) and 1.35 ± 0.07 (p = 0.002) for GdNPs and IONPs, 
respectively. In terms of comparing enhancements between NPs, 
with U87 cells, there were significant differences between AuNPs 
and GdNPs (p = 0.026), then GdNPs and IONPs (p = 0.023). With 
MCF-7 cells, significant differences were shown between AuNPs 
and IONPs (p = 0.003), then GdNPs and IONPs (p = 0.034). 
When comparing the same NP between the two cell lines, a sig-
nificance in EF was only demonstrated with AuNPs (p* = 0.004).
2.5. DNA DSB Damage
Figure 5 demonstrates DNA DSB damage following irradiation, 
where changes in foci were quantified at two time points, with 
and without NPs. Examples of images of cells following immu-
nofluorescence staining are shown in Figure 6. From Figure 5, 
it can be seen that the addition of NPs causes changes in the 
number of foci per cell at both time points, where considering 
the means, the differences were shown to be statistically sig-
nificant in all cases tested. For both cell lines, the greatest 
residual damage was shown with IONPs when considering the 
third quartile (108% and 40% greater and the control for U87 
and MCF-7, respectively, compared to 67% and 20% for both 
AuNPs and GdNPs). Interestingly, however, when considering 
immediate damage with U87 (30-min time point), the greatest 
damage was shown with AuNPs, although a significant portion 
remained unrepaired (24-h time point); the NPs that showed 
the least repair were IONPs. Considering the 24 h data, it can 
be seen from Figure 5 that for U87 cells, AuNPs and GdNPs 
show comparable results in terms of the first and third quar-
tiles and the median, with similar distributions shown, whereas 
IONPs showed the greatest spread and highest median value. 
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Figure 3. Cell survival curves for A) U87 and B) MCF-7, where for both cell lines, cells + AuNPs, cells + GdNPs or cells + IONPs were assessed, as 
well as a control of cells alone. Samples were irradiated with X-rays from a 6 MV linac in triplicate. NPs added at a concentration of 0.5 mg mL−1 
and incubated for 24 h.
Table 1. Fitting parameters, alpha and beta for each sample, along with the ratios and p-values, highlighting significance between control and NP 
samples, based on a t-test.
Sample α [Gy−1] β [Gy−2] Ratio [Gy] p-Value1 p-Value2 p-Value3 p-Value4 p-value5
U87 cells 0.259 ± 0.030 0.043 ± 0.007 6.02 ± 1.19
U87 cells + AuNPs 0.404 ± 0.086 0.020 ± 0.007 20.5 ± 8.73 0.047 0.170
0.049
U87 cells + GdNPs 0.689 ± 0.173 0.008 ± 0.003 86.1 ± 41.5 0.029 0.143
0.999
U87 cells + IONPs 0.401 ± 0.044 0.020 ± 0.008 20.5 ± 8.90 0.049 0.772
0.049
MCF-7 cells 0.256 ± 0.035 0.042 ± 0.007 6.15 ± 1.32
MCF-7 cells + AuNPs 0.575 ± 0.029 0.015 ± 0.006 39.3 ± 17.4 0.030
0.983
MCF-7 cells + GdNPs 0.520 ± 0.049 0.013 ± 0.005 39.6 ± 15.6 0.021
0.229
MCF-7 cells + IONPs 0.432 ± 0.042 0.019 ± 0.009 22.9 ± 9.91 0.044
0.193
The first p-value represents comparisons between each respective NP and the control without NPs, whereas the second compares AuNPs and GdNPs, the third AuNPs 
and IONPs, the fourth GdNPs and IONPs, and the fifth compares the same NP between the two cell lines considered.
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With MCF-7 cells, the means were the same; however, the 
spreads differed, leading to the median value of GdNPs being 
lower than both AuNPs and IONPs. As with U87 cells, IONPs 
showed the greatest spread for MCF-7 cells. These deviations 
from a Gaussian distribution can indicate the presence of a 
subpopulation of cells that have responded differently to the 
treatment of ionizing radiation combined with NPs.
2.6. Effect of Cellular Elemental Uptake on Enhancement
Figure 7 shows that for the cell lines and NPs used, at an incu-
bation concentration of 0.5 mg mL−1, there was a non-linear 
inverse relationship between cellular elemental uptake and 
enhancement. Although significance was shown between cells 
with no NPs and cells with NPs for both cell lines (Figure 4), 
the level of enhancement did not increase with elemental 
uptake. An example of this can be seen with U87 cells, where 
IONPs showed the highest elemental uptake but the lowest 
level of enhancement. It should be noted, however, that ele-
mental uptake does not directly correlate to NP uptake due to 
differences in structures, molecular weights, compositions, and 
sizes of NPs considered, where the highest elemental uptake 
may not correspond to the highest number of NPs internalized. 
Therefore, only the total amount of material per cell was consid-
ered, rather than converting into approximate number of NPs 
per cell. Figure 7 consequently demonstrates the relationship 
between the total amount of material and the enhancement 
effect, through the EF, suggesting the presence of an optimum 
uptake. The control represents any cell that was not exposed to 
NPs, where, by definition, there would be no enhancement or 
uptake to measure.
When comparing the same NP between the two cell lines, it 
was interesting to note that significance was demonstrated in 
EF between AuNPs, but not in elemental uptake, whereas with 
IONPs, significance was shown in elemental uptake but not in 
the EF. The same trends were shown in the residual damage 
(Figure 8) for both IONPs and AuNPs; with GdNPs, however, 
no significance was shown in elemental uptake or EF, but was 
shown in terms of residual damage.
3. Discussion
Considering the clonogenic assay work, it was evident from the 
results that the addition of NPs created a significant decrease 
in cell survival (Figure 4). Although this decrease was observed 
for both cell lines and both NP types, the rate of decrease dif-
fered between the two variables. From Table 1, it was evident 
that the addition of NPs both increased the alpha value, indi-
cating more cells killed per Gy and decreased the beta value, 
suggesting a smaller proportion of repairable cell damage. 
Together, these led to higher statistically significant α/β ratios 
for both cell lines and NPs. For both cell lines, the greatest ratio 
increase was with GdNPs. It was found that the control value 
for U87 cells (no NPs) reported in this study, was comparable 
to those quoted in the literature for cells irradiated with 6 MV 
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Figure 4. Enhancement factors calculated from clonogenic cell survival 
fittings comparing doses needed for equivalent cell survival at a dose 
of 2 Gy for the control sample. The p-value within the bar represents 
comparisons between each respective NP and the control, the p* value 
represents the comparison of the same NP between the two cell lines, 
whereas the values above the bars compare the different NP types for 
each cell line.
Figure 5. Quantitative analysis considering the effect of AuNPs, GdNPs, and IONPs on DSBs formation in a) U87 cells (left) and b) MCF-7 cells (right). 
Samples were exposed to 1 Gy using 6 MV X-rays, quantifying foci per cell. The lower part of the boxes indicates the first quartile, dividing line shows 
the median, square shows the mean, and top line shows the third quartile. The lower and upper ends of the whisker indicate 10th and 90th percentile. 
For each data point, 50 cells were counted for three independent replicates, where the individual counts are depicted to the left of each respective box, 
with a normal distribution.
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X-rays,[33–35] where values ranged between 5 and 10 Gy and 
our value was 6.02 ± 1.19 Gy. The MCF-7 control (no NPs) was 
also comparable to those in the literature which ranged from 
2 to 10 Gy.[36,37]
When comparing the ratios of the same NPs between the two 
cell lines, no significance was demonstrated for all NPs consid-
ered, highlighting that the NPs had an effect on cell kill irre-
spective of the cell line considered. In terms of enhancement, 
a statistically significant increase in enhancement was demon-
strated with all NPs and cell lines (Figure 4). This correlated 
with statistically significant changes in the formation of DSBs 
(Figures 5 and 6). An example of this was with U87 cells and 
GdNPs, where the β component was significantly decreased in 
the cell survival and the residual damage showed a significant 
increase. In terms of the residual damage, however, the greatest 
change in foci per cell was shown with IONPs for U87 cells, 
which showed the lowest ratio increase in 
terms of cell survival. This highlights that the 
enhancement due to NPs is complex and not 
only due to an increase in DNA damage.
Similar findings in DNA damage were 
reported by Taggart et al., where they also 
considered the use of a breast and glioma 
cell line (MDA-MB-231 and T98G, respec-
tively). With this study, they only considered 
one NP type, the same commercial AuNP 
used in this study; however, they irradiated 
their samples using 225 kVp X-rays, rather 
than the 6 MV linac used in this study. They 
demonstrated statistically significant increase 
in DNA damage with the breast cancer cell 
line; however, with the glioma cell line, they 
showed a statistically significant decrease in 
DNA damage.[38]
Another factor for the treatment was 
the radiation type used, as it is known that 
when irradiating with higher LET radiation, 
the survival curve is steeper, which indicates less repaired 
damage. The linear survival curve with particle radiation is due 
to an increasing alpha value with increasing LET,[39] indicating 
a higher α/β ratio than X-rays, where a point of interest was 
to identify if the addition of NPs to cells irradiated by X-rays 
could show comparable damage to that observed with higher 
LET radiation. From the work of Chaudhary et al., the α/β ratio 
for U87 cells irradiated by protons at an LET of 11.9 keV µm−1 
was approximately 10 Gy.[40] Our findings show higher values 
than this for both types of NPs (2.0, 8.6, and 2.0 times higher 
for Au, GdNPs, and IONPs, respectively), indicating a more 
linear survival curve, similar to that seen with protons, but in 
our case, even steeper than protons for both NPs. This suggests 
that the addition of NPs increases the biological effectiveness 
of the treatment, offering comparable damage to that of higher 
LET radiation.
In comparison to the study by Stefancikova et al., which 
also used GdNPs, a previous formulation of the commercial-
ized AGuIX NPs, and U87 cells irradiated with X-rays (cobalt 
source compared to measurements with a linac in this study), 
at a concentration of 0.5 mg mL−1 (12 h incubation com-
pared to 24 h used in our study), there was a difference in 
the observed EF, where they report a factor of 1.23, whereas 
this study found a value of 2.02.[41] A possible reason for this 
difference is that although both considered GdNPs and the 
same cell line, incubation times differed. The longer incuba-
tion time would have led to different number of NPs internal-
ized within the cell, resulting in a different EF; however, this 
study did not quote the average amount of Gd taken up within 
a cell.
For comparisons to be made between the NP types and 
cell lines used, quantification of the cellular elemental uptake 
was needed (Figure 2). It was theorized that a higher level of 
elemental uptake would correlate with a higher enhancement 
effect, where only elemental uptake was considered rather 
than converting values to approximate number of NPs. This 
was chosen as in practice differences in molecular weights, 
compositions, coatings, and final size due to the protein 
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Figure 6. Immunofluorescence performed for 53BP1 foci analysis using a CellInsight CX5High 
Content Screening Platform (×20 magnification) to image the samples for both U87 (left) 
and MCF-7cells (right).
0 1 2 3 4 5 6
Cellular uptake (pg/cell)
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1.2
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1.6
1.8
2
2.2
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EF
Control
MCF-7+AuNPs
MCF-7+GdNPs
MCF-7+IONPs
U87+AuNPs
U87+GdNPs
U87+IONPs
Figure 7. Comparisons between the enhancement factors and cellular 
elemental uptake for each respective setup, where control represents any 
cell without NPs, where the uptake would be 0 and there would be no 
enhancement; therefore, the EF would be 1. The p-values comparing the 
cellular elemental uptake for the same NP across the two cell lines were 
0.794, 0.426, and 0.008 for Au, Gd, and IONPs, respectively. Comparing 
the EF for the same NP across the two cell lines, the p-values were 0.005, 
0.111, and 0.147 for Au, Gd, and IONPs, respectively.
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corona would alter the number of NPs internalized within the 
cell. Therefore, by considering the bulk elemental material, we 
can make comparisons on the effect this has on the enhance-
ment effect of cells exposed to NPs of an equal incubation 
concentration. Within this study, the complex nature of NP-
enhanced radiotherapy was demonstrated, where with regards 
to the cellular uptake of bulk NP material, it was suggested 
that there was an optimum level of uptake to observe the 
highest enhancement effect. Figure 7 shows that although the 
highest level of elemental uptake was demonstrated with iron 
oxide, it did not correlate with the highest enhancement factor. 
Similarly, when considering the same NP, GdNPs with U87 
cells showed the highest biological effect in terms of EF yet 
had a lower level of elemental uptake compared with MFC-7 
cells; however, no significance was demonstrated in terms of 
elemental uptake between these cell lines for GdNPs. In con-
trast, significance was shown in elemental uptake for IONPs, 
where a higher enhancement was shown at a lower uptake; 
whereas in terms of enhancement, no significance was shown 
between the cell lines.
Interestingly, Figure 8 shows the inverse, whereby for all 
NPs and cells considered, a higher level of residual damage 
was shown with a higher elemental uptake. From these find-
ings, the complexity of mechanisms regulating radiobiological 
enhancement can be seen, where the initial enhancement 
could be due to the combined effect of physical, chemical, and 
biological mechanisms. At higher levels of elemental uptake, 
however, if higher elemental uptake correlated with a higher 
number of NPs, the effect of these mechanisms would be 
altered, where physical enhancement may be reduced due to 
secondary electrons being absorbed in neighboring NPs. Simi-
larly, a higher number of NPs could act as ROS scavengers, 
reducing the amount of ROS present to damage the cell,[42] 
thereby reducing both chemical and biological enhancement. 
Other cellular responses, resulting in biological mechanisms 
such as oxidative stress and cell cycle effects could have 
caused differences in the biological effect, which may not be 
dependent on a higher level of elemental uptake.
4. Conclusion
This study was able to demonstrate bio-
logical changes encountered by cells due 
to the presence of NPs combined with ion-
izing radiation. It was possible to quantify 
differences between both cell lines and NP 
types. In terms of the clonogenic assays 
with U87 cells, an enhancement of dose was 
observed, whereby a lower dose needed to be 
delivered (0.98 Gy with GdNPs compared to 
2 Gy without NPs) to offer the same level of 
cell survival as that observed with cells alone 
at 2 Gy. This study has highlighted the com-
plex relationship between elemental uptake 
and enhancement effect both in terms of 
cell survival and DNA damage. It was shown 
that when considering the same NP between 
the two cell lines, a higher enhancement 
effect was related to lower cellular elemental 
uptake, whereas the DNA damage increased 
with increasing elemental uptake. This alluded to differences 
in contribution from mechanisms highlighted in the litera-
ture, changing with increasing elemental uptake. Although 
significance in enhancement was demonstrated by comparing 
NP-inoculated to NP-free samples, significance was only dem-
onstrated for AuNPs when comparing the same NP between 
the two cell lines. This therefore indicates that the NP type, 
elemental uptake, or cell type alone cannot explain the radio-
biological enhancement effect observed with the NPs and cell 
lines used in this study. Further work would be to investigate 
different combinations of these parameters to explain the 
effects observed. One aspect would be to consider different 
incubation concentration to demonstrate if an optimum uptake 
can be identified. Others would be to use specific assays to 
highlight the different mechanisms in place to demonstrate 
their overall contribution to cell kill following NP-enhanced 
radiotherapy.
5. Experimental Section
Cell Culture: Two cell lines were investigated, MCF-7 human breast 
adenocarcinoma cell line and U87 human glioblastoma cell line. Both 
cell lines were cultured in Minimum Essential Medium (MEM) (Fisher 
Scientific, UK), supplemented with 10% fetal bovine serum and 1% 
penicillin–streptomycin (Fisher Scientific, UK). All cells were maintained 
in monolayers in a tissue culture incubator at 37 °C with 5% CO2/95% 
air.
Nanoparticles: Three nanoparticles were investigated; the first 
were freeze-dried spherical AuNPs (Aurovist) with a mean diameter 
of 1.9 ± 0.6 nm (Nanoprobes Inc, NY, USA) that were re-dispersed in 
phosphate buffered saline (PBS) (Fisher Scientific, UK) and stored at 
20 °C as per the manufacturer’s instructions. The second were freeze-
dried gadolinium-based nanoparticles (AGuIX) with a mean diameter 
of 3 ± 1.5 nm (NH TherAguix, France). These were re-dispersed in 
ultrapure water and stored at 4 °C. The third were magnetic dextran iron 
oxide nanoparticles (RCL-01) in water with a mean (Z-average) diameter 
of 140 ± 4 nm and a polydispersity index of 0.25 ± 0.02 (Resonant 
Circuits Limited, UK), stored at 4 °C. All stock solutions were diluted in 
culture medium before adding a concentration of 0.5 mg mL−1 of each 
respective NP material to the seeded cells.
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Figure 8. Comparisons between the residual DNA damage and cellular elemental uptake for 
each respective setup. The p-values represent comparisons between the two cell lines for the 
same NP.
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Nanoparticle Toxicity: To ensure the concentrations used were 
non-toxic, a fixed number of cells were seeded onto six-well plates 
(Sigma-Aldrich, UK), one plate for each cell line, where two concentrations 
of each nanoparticle were introduced. From the literature, it was reported 
that a concentration of 0.5 mg mL−1 (24 h incubation) was not toxic; 
therefore, this and a lower concentration of 0.2 mg mL−1 were tested.[18] 
Following the incubation period, medium and nanoparticle mixture was 
removed, wells were gently washed twice with PBS, and each well was 
filled with 5 mL of fresh medium. The plates were incubated for 10–14 
days, fixed, stained, and colonies were counted and compared to control 
plates without NPs.
Sample Preparation: Having confirmed the concentration of 
0.5 mg mL−1 was not toxic, a clonogenic assay investigation was 
conducted in triplicate. For the irradiations, 105 cells mL−1 were seeded 
onto 35 mm culture dishes (Corning, UK) 48 h prior to irradiation, to 
reach between 80–100% confluence on the day of irradiation. The NP 
samples were incubated for 24 h prior to irradiation with 1 mL medium 
containing NPs at a concentration of 0.5 mg mL−1. Medium was also 
changed for the control samples 24 h prior to irradiation. Following 
the incubation period and just prior to irradiation, NP solution was 
removed, the samples were gently washed twice with PBS to remove any 
extracellular NPs, and fresh medium was added to each dish.
Uptake Measurements: As with previous samples, cells were seeded, 
and NPs were added. Following the incubation period, the NP solution 
was removed, and dishes were gently washed twice with PBS. Cells 
were trypsinized and counted with a hemocytometer to determine the 
total number of cells per sample. The cell suspension was centrifuged 
for 15 min at 1000 RPM. Pellets were then dissolved by aqua regia 
(three parts hydrochloric acid to one part nitric acid) and the solution 
was diluted with ultrapure water. Using ICP-MS (Agilent 8800, 
Cheadle, UK), reference measurements were initially carried out on 
a known concentration of each NP type, diluted to obtain a reference 
curve relating the counts per second to the NP concentration.[43] Each 
sample was then processed, and counts were related to the reference 
curve to determine the elemental concentration of each material per 
sample. Results were then reported as the mass of NP element per cell 
(pg per cell).
Irradiation: For clonogenic X-ray irradiations, five dose points were 
investigated in triplicate, 0, 1.5, 3, 4.5, and 6 Gy, chosen to decrease 
the survival fraction by approximately two orders of magnitude 
to give a sufficient cell survival curve fitting for each cell line and 
nanoparticle combination, whereas the DNA damage samples were 
irradiated with 1 Gy. Before irradiating with X-rays, the dishes were 
filled with medium, providing adequate scattering conditions. The 
dishes were then sealed using Parafilm M (Sigma-Aldrich, UK) 
immediately before irradiation. Irradiations were carried out at the 
National Physical Laboratory, Teddington, UK, with a 6 MV linac 
(Elekta Versa HDTM), with a dose rate of 6.5 Gy min−1. Dishes 
were placed in the center of a 10 × 10 cm2 field (Figure 9), where 
dose calculations were based on reference conditions using depth 
dose data from ionization chamber measurements for this field 
size. The dose output was also confirmed with ionization chamber 
measurements traceable to the UK primary standard. The beam 
uniformity was assessed using Gafchromic EBT3 film (Ashland ISP 
Advanced Materials, NJ, USA), where the dose variation across the 
sample was less than 2%.
Clonogenic Assay: Following irradiation, each flask was washed twice 
with PBS, trypsinized, counted, and re-plated onto six-well plates and 
incubated for 10–14 days.[44] Following this, colonies were stained with 
0.4% crystal violet and counted using a Nikkon Eclipse Ti-S inverted 
microscope. The plating efficiency was calculated as the ratio of the 
colonies formed to cells seeded. The surviving fraction (SF) was 
calculated as the plating efficiency of the irradiated sample divided by 
the plating efficiency of the unirradiated sample. The SF was plotted 
against the dose, where the curves were then fitted to the LQ model 
described by Equation (1)
SF e
2D D
=
α β( )− +
 (1)
where α and β are fitting parameters and D is the delivered dose. 
α and β values were determined from the curve fitting, carried out 
using OriginPro software, version 9 (OriginLab Inc., Northampton, 
MA), using a non-linear least-squares fitting procedure, weighted to 
the errors associated with each measurement. From this the α/β ratio 
was determined for each curve. The enhancement factor (EF) was 
determined as the ratio of dose required for NP treated cells to give 
same survival as cells not treated with NPs, irradiated at 2 Gy, where the 
ratios were determined using the SF fits (Equation (2)).
EF
Reference dose of 2 Gy
Dose needed with Cells NPs to achieve the same cell survival as Cells alone at a dose of 2 Gy
=
+  
(2)
Statistical analysis was performed using a t-test with the statistical 
software SPSS (IBM Corp). Significance was tested both between 
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Figure 9. Schematic demonstrating the irradiation setup with the distances between the source and the sample surface. Dose was established fol-
lowing TRS398 Code of Practice and scaled to the correct depth for the cells at the bottom of the petri dish using the percentage depth dose curves (A). 
Experimental setup for clonogenic assay irradiations using 6 MV X-rays, where the sample was placed on blocks of solid water in a 10 × 10 cm2 field (B).
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samples containing NPs compared to control samples and between the 
different NP samples.
Foci Formation Assay: For the staining of the DNA damage marker 
53BP1, samples were fixed at two timepoints, one 30 min post-irradiation, 
another after 24 h, demonstrating the immediate and unrepaired damage 
post-irradiation respectively, the latter being referred to as the ‘residual 
DNA damage’ or ‘residual damage’ of the samples. Medium was 
removed and each dish was washed twice with PBS. Cold fixing solution 
(methanol:acetic acid) was added to each dish and left for 30 min 
at 4 °C. The solution was then removed and replaced with PBS where 
samples were stored at 4 °C until immunofluorescence staining. In terms 
of the staining, samples were washed with cold PBS, permeabilized 
(0.5% Triton X-100 in PBS), and blocked in 10% goat serum, 1% BSA, 
and 0.1% Triton X-100 in PBS for 1 h at 37 °C in an incubator. Cells were 
probed with 53BP1 primary antibody raised in rabbit (Novus Biologicals, 
USA) at a dilution of 1:1000 and incubated at 37 °C for an hour. Samples 
were washed three times, then probed with goat anti-rabbit Alexa Flour 
488-conjugatedsecondary antibody (Invitrogen, Life Technologies, USA) 
at a dilution of 1:1000 (samples were covered from this point due to 
light sensitivity), and incubated for an hour. Samples were then washed 
three times and counterstained with DAPI (Sigma-Aldrich, UK) where 
they were then imaged using the CellInsight CX5 High Content Screening 
Platform (Thermo Fisher Scientific, Inc). For each data point, foci were 
manually randomly counted in 50 cells, where each point had triplicate 
experiments. Statistical significance was determined using a t-test.
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